News Astellas buys Ogeda after menopause drug impresses Japanese pharma swoops after strong phase 2a results.
Views & Analysis Astellas wins first Real-World Evidence prize at UK awards UK awards first to introduce a real-world evidence category.
UK & Europe Astellas censured for breach of ABPI code Astellas has been taken to task for breaching the UK pharma industry's self-regulatory Code of Practice during an event convened to discuss its prostate cancer therapy Xtandi in Italy last
News Astellas files new drug for life-threatening infections A new treatment for life-threatening infections most commonly affecting immunocompromised cancer patients has been filed with the FDA.
News Immunovant's thyroid eye disease drug flunks pivotal trials Immunovant shares were sliding today after it reported that FcRn blocker batoclimab failed a pair of phase 3 trials in thyroid eye disease.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
